 limit efficaci haemophilu influenza type conjug vaccin alaska nativ infant alaska vaccin studi group background prevent invas haemophilu influenza type diseas vaccin effect first month life infant alaska nativ high risk invas influenza type diseas method protect efficaci influenza type polysaccharide-diphtheria toxoid conjug vaccin polyribosylribitol phosphate-diphtheria toxoid prp-d alaska nativ infant random double-blind placebo-control trial vaccin salin placebo month age result subject-year follow-up episod influenza type diseas overal incid invas diseas vaccin subject case patient-year placebo control alaska nativ infant dose signific protect efficaci vaccin efficaci percent percent confid interv lack efficaci age onset diseas age immun type diseas degre alaska nativ heritag time immun year studi level influenza type anticapsular antibodi recipi vaccin level placebo second third dose third dose percent vaccin infant antibodi level microgram millilit geometr mean titer antibodi respons vari level antibodi degre alaska nativ ancestri age time first second immun age time third dose conclus evid prp-d vaccin signific protect alaska nativ infant invas diseas influenza type ineffect vaccin limit immunogen